Abstract:AMP-activated protein kinase (AMPK) is an energy sensor and a key regulator of cell metabolism, hence a promising drug target. Point mutations in the regulatory γ2-subunit (encoded by PRKAG2 gene) have been shown to cause a unique form of cardiomyopathy in humans characterized by cardiac growth, arrhythmias and glycogen storage. In previous studies, we demonstrated that the mutation of prkag2 (N488I) caused aberrant activation of AMPK leading to glycogen storage. However, elimination of glycogen storage by inhibiting glycogen synthase activity failed to normalize heart weight (HW) of the mutant mice. Here, we aimed to determine whether cardiac growth in PRKAG2 ardiomyopathy was dueto cellular hypertrophy or hyperplasia. We used transgenic mice expressing a mutant PRKAG2 (N488I) in the heart (TGγ2 N488I ) that faithfully recapitulated PRKAG2 cardiomyopathy. We determined HW and cardiac myocyte size in adult (2 months) and postnatal (2 weeks) hearts in WT and TGγ2 N488I . At 2 months, TGγ2 N488I hearts show a 2.4-fold increase in HW/BW (body weight) (10.3 ± 1.44 vs. 4.3± 0.17 mg/g) as well as cross-sectional cell surface area compared WT hearts (325 ± 13 vs. 155 ± 5.4 μm 2 ,p<0.01), suggesting cellular hypertrophy in adult TGγ2 N488I heart. Furthermore, we observed increased mTOR activity evidenced by enhanced phosphorylation of mTOR (Ser2448) as well as its downstream targets S6 and 4E-BP. The HW of TGγ2 N488I was partially inhibited by treatment with rapamycin, an inhibitor of mTOR. Interestingly, the length and width of isolated cardiomyocytes from 2 weeks old mice were not different between the WT and TGγ2 N488I heart in spite of a 50% increase of HW of TGγ2 N488I mice. We observed a 2- fold increase in the expression of a proliferation marker, proliferating cell nuclear antigen (PCNA) during postnatal cardiac growth. Expression of Cyclin genes including cyclin D1, D2 and E1 was greatly increased in TGγ2 N488I hearts (2.4 - 4 fold, p<0.01 vs. WT). Taken together, these data indicate that aberrant γ2-AMPK activation stimulates cardiac growth through increased cell number during postnatal growth period and increased cell size at adulthood. These results suggest a novel role of γ2-AMPK in the growth of cardiac myocytes.

GPR39 promotes cardiac hypertrophy by regulating the AMPK–mTOR pathway and protein synthesis

GRP78 (Glucose-Regulated Protein of 78 Kda) Promotes Cardiomyocyte Growth Through Activation of GATA4 (Gata-Binding Protein 4)

GW24-e2121 Adenosine Monophosphate-Activated Protein Kinase Attenuates Cardiomyocyte Hypertrophy Through Regulation of FOXO3a/MAFbx Signalling Pathway

Adipor1/Appl1 Potentiates the Protective Effects of Globular Adiponectin on Angiotensin Ii-Induced Cardiac Hypertrophy and Fibrosis in Neonatal Rat Atrial Myocytes and Fibroblasts

Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway

Gαq‐PROTEIN CARBOXYL TERMINUS IMITATION POLYPEPTIDE GCIP‐27 ATTENUATES CARDIAC HYPERTROPHY IN VITRO AND IN VIVO

Long-Term Activation of Adenosine Monophosphate-Activated Protein Kinase Attenuates Pressure-Overload-Induced Cardiac Hypertrophy

Activation of AMPK Inhibits Cardiomyocyte Hypertrophy by Modulating of the FOXO1/MuRF1 Signaling Pathway in Vitro

Tumor Suppressor Gene ING3 Induces Cardiomyocyte Hypertrophy Via Inhibition of AMPK and Activation of P38 MAPK Signaling

Abstract 73: Aberrant Activation of γ2-AMPK Increases Cardiac Growth Through Cellular Hypertrophy and Hyperplasia

GDH Promotes Isoprenaline-Induced Cardiac Hypertrophy by Activating Mtor Signaling Via Elevation of Α-Ketoglutarate Level

Transactivated EGFR Mediates Α₁-Ar-induced STAT3 Activation and Cardiac Hypertrophy.

Peroxisome proliferator–activated receptor gamma coactivator 1 alpha protects cardiomyocytes from hypertrophy by suppressing calcineurin-nuclear factor of activated T cells c4 signaling pathway

Protection Against Cardiac Hypertrophy by Geniposide Involves the GLP‐1 Receptor / AMPKα Signalling Pathway

Cd38 Promotes Angiotensin Ii-Induced Cardiac Hypertrophy

MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A.

Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways

Citri reticulatae Pericarpium attenuates Ang II-induced pathological cardiac hypertrophy via upregulating peroxisome proliferator-activated receptors gamma

Growth/differentiation Factor 1 Alleviates Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction.

PFKP inhibition protects against pathological cardiac hypertrophy by regulating protein synthesis

Atrial Natriuretic Peptide Inhibits Cardiomyocyte Hypertrophy Through Mitogen-Activated Protein Kinase Phosphatase-1